PTx Buys ex-Sanofi Anti-Radiation Drug Leukine Because These Days You Never Know! | Pharmaguy's Insights Into Drug Industry News |

Partner Therapeutics, a Boston startup formed last week by a pair of Merrimack and Seragon executives, has made its first move: it’s acquired an ex-Sanofi cancer drug with hopes that the FDA will OK it for radiation poisoning. Like… the kind from an atomic bomb or a nuclear plant disaster.


Seems like a rare and uncommon event to target, but founder and CEO Bob Mulroy says it’s best to be prepared.


“You would hope you’d never need a drug like this for this kind of incident,” Mulroy told The Boston Globe. “But I think that, should an incident like that occur, being prepared for it is a very important thing.”


The Globe and others are positing that insults slung between President Trump and North Korean leader Kim Jong Un are fueling fears of nuclear war, leading to demand from people and governments to stockpile radiation sickness drugs.


The medicine is called Leukine, and it’s currently approved to treat acute myeloid leukemia patients fighting infections after undergoing bone marrow transplants. But data presented at the 2016 American Society of Hematology meeting showed Leukine’s ability to boost survival in monkeys exposed to radiation if injected 48 hours after exposure. That’s interesting, considering Amgen’s radiation sickness drugs Neupogen and Neulasta must be injected almost immediately after exposure to radiation for it to work.